Hofseth Biocare unveils ProGo: dual action GLP-1 and muscle protection

Hofseth BioCare (HBC) has announced the release of a whitepaper for ProGo, described as the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection. ProGo uniquely combines GLP-1 receptor agonism with targeted inhibition of Myostatin and Activin A pathways, both negative regulators of muscle mass. This triple-action approach aims to protect lean muscle during weight loss, offering highly absorbable protein, antioxidant properties, and anti-inflammatory bioactivity.

ProGo is a fully traceable nutritional supplement derived from hydrolysed peptides and collagen, featuring a complete amino acid profile, including high levels of BCAAs. HBC highlights ProGo's superior bioavailability due to its smaller peptide size. The company, which upcycles salmon industry side streams, also markets OmeGo whole salmon oil and CalGo/NT-II salmon bone powder.

HBC has spun out HBC Immunology, a biotech-focused company that has secured external finance and is developing therapeutics for prostate cancer, ovarian cancer, and asthma. Hofseth BioCare ASA is listed on the Oslo Stock Exchange.